Health News Releases

  • Today December 20
May 21, 2019 10:17
New Study Evaluates Ability of Masimo SpHb® (Noninvasive Hemoglobin) to Estimate Timing for Invasive Measurement to Detect Anemia During Surgery
Masimo (NASDAQ: MASI) announced today the results of a study published in BMC Anesthesiology in which clinicians at Peking Union Medical College in Beijing evaluated the ability of noninvasive and con
May 20, 2019 11:20
Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought
ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thora
May 20, 2019 10:19
New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week®
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic ve
May 20, 2019 09:42
WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology
The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019. ASCO® endorsed for the past 11 years, the WIN symposium will deliver an exciting line-up of speakers
May 17, 2019 15:32
Takeda Reports FY2018 Full Year Results and Issues FY2019 Guidance
Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190513005951/en/ FY2018
May 17, 2019 13:44
German Diabetes Clinic Increases Diabetic Retinopathy Screenings From Zero to Thousands After Implementing Eyenuk’s EyeArt AI Eye Screening System
Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results of its expansion int
May 17, 2019 13:27
Takeda and London School of Hygiene & Tropical Medicine Establish “Takeda Chair in Global Child Health”
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) and the London School of Hygiene & Tropical Medicine (LSHTM) will announce today at the evening reception, hosted by the Embassy
May 17, 2019 09:30
EcoTT Set on Taking over the Global Market with Hanji Safety Mask and Konjac with Dark Temptation, a Snack for Weight Control
EcoTT Co., Ltd., a Korean general trading company, announced the plan to launch its new products including Novrect Hanji Safety Mask and Konjac with Dark Temptation, a snack for weight control, on Ama
May 17, 2019 08:52
SpinalCyte Launches Initiative to Highlight Advances in Fibroblast Technology
SpinalCyte, LLC, a clinical stage regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced a new comprehensive resource to raise awar
May 16, 2019 19:49
Trial results of Pradaxa® vs ASA in ESUS published in NEJM
Boehringer Ingelheim today announced full results from the RE-SPECT ESUS® trial, a Phase III randomised, double-blind study investigating the efficacy and safety of Pradaxa® (dabigatran etexilate) ver
May 16, 2019 10:45
Q3 Medical Devices Limited Enters into a Distribution Agreement with Medtronic for its Biodegradable Biliary and Pancreatic Stent
Q3 Medical Devices Limited (“Q3 Medical”) based in Dublin, Ireland, announced today that it has entered into a distribution agreement with Medtronic plc for ARCHIMEDES, the first to market fully biode
May 16, 2019 08:51
LifeArc and GVK BIO Celebrate a Decade of Partnership, Transforming Research into Life-Saving Medicines
GVK BIO, a leading global Contract Research and Development Organisation (CRDO), and LifeArc, one of UK’s top medical research charities, are pleased to announce the 10th anniversary of a successful p
May 15, 2019 17:15
Takeda to Highlight New Research into the Long-term Complications of Chronic Hypoparathyroidism at the European Congress of Endocrinology 2019 Annual Meeting
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will feature 7 presentations, including one oral presentation, at the upcoming European Congress of Endocri
May 15, 2019 11:55
SpeeDx Receives Clearance for PlexPCR Respiratory Virus Test
SpeeDx Pty. Ltd. today announced the clearance of the PlexPCR® RespiVirus* test from the Australian Therapeutic Goods Administration (TGA). The test utilises market-leading PlexPCR® technology to dete
May 14, 2019 10:15
Masimo and Mindray Announce Expanded Partnership
Masimo (NASDAQ: MASI) and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE: 300760) announced today that they have entered into a purchase and license agreement, under which Mindray will offer
May 14, 2019 08:50
TRIGR Therapeutics Announces Formation of Global Clinical & Scientific Advisory Board
TRIGR Therapeutics, Inc. (“TRIGR”), a clinical stage biotechnology company focused on the development of multi-targeted and immunomodulatory bispecific antibodies, announced today the formation of its
May 10, 2019 13:16
Takeda Expands Oncology Research, Demonstrating Commitment to Patient Community at 15th International Symposium on Myelodysplastic Syndromes
Takeda Pharmaceutical Company Limited [TSE: 4502 / NYSE: TAK] today announced that it will present a total of five company-sponsored poster presentations, as well as an oral pipeline symposium, at the
May 10, 2019 09:27
U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation of Vedolizumab (Entyvio®) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for a
May 09, 2019 10:24
Takeda Simplifies Portfolio and Accelerates Deleveraging Through Two Divestitures
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into agreements to divest its Xiidra® (lifitegrast ophthalmic solution) 5% product (“Xiidra®”)
May 08, 2019 09:20
Analysis Showed Oral Ozanimod Reduced Brain Volume Loss Across All Age Subgroups in Adults with Relapsing Multiple Sclerosis
Celgene Corporation (NASDAQ:CELG) today announced the results of a post-hoc analysis of data from the Phase 3 RADIANCE™ Part B trial showing that ozanimod reduced cortical grey matter volume loss vers
May 03, 2019 16:40
Apax Funds, CPPIB and PSP Investments Agree to Sell Acelity and its KCI Subsidiaries to 3M for $6.725 Billion
A consortium comprised of funds advised by Apax Partners (the “Apax Funds”), together with Canada Pension Plan Investment Board (“CPPIB”) and the Public Sector Pension Investment Board (“PSP Investmen
April 30, 2019 17:30
Eyenuk’s AI Eye Screening System For Diabetic Retinopathy Demonstrates Exceptional Performance In A Prospective, Multi-Center, Pivotal Clinical Trial
Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results from its landmark p
April 30, 2019 15:00
tHIS 2019 to Shape Future Health Science and Technology With Expanded Exhibition Scale in Shanghai and Hangzhou
The Health Industry Summit (tHIS) 2019, organized by Reed Sinopharm, will scale up with a total exhibition area of 400,000m2. For the first time, it will adopt the “Two Cities One Show” mode - to be l
April 30, 2019 14:00
Hospitals in Taiwan Make a Commitment to Eliminate Preventable Patient Harm & Death in Hospitals
The Patient Safety Movement Foundation (PSMF) and the Taiwan Patient Safety Culture Club (TPSCC) announced today that 4 hospitals and 1 healthcare organization made a public commitment to helping elim
April 30, 2019 11:50
Masimo Announces First CE-marked Third-party Masimo Open Connect® Module for the Root® Patient Monitoring and Connectivity Hub
Masimo (NASDAQ: MASI) and Mdoloris Medical Systems announced today the CE marking of the Mdoloris Analgesia Nociception Index (ANI®) module for the Masimo Root® Patient Monitoring and Connectivity Hub
25 per page50 per page75 per page100 per page